Targeting high-grade B cell lymphoma with CD19-specific T cells
Lehmann FM, Maurberger A, Feicht S, Helm F, Ladinig C, Kieback E, Uckert W, Kammertoens T, Kremmer E, Mautner J, Gerbitz A, Bornkamm GW (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Publisher: Wiley-Blackwell
Book Volume: 135
Pages Range: 1153-64
Journal Issue: 5
DOI: 10.1002/ijc.28760
Abstract
Adoptive T cell therapy is an important additional treatment option for malignant diseases resistant to chemotherapy. Using a murine high-grade B cell lymphoma model, we have addressed the question whether the B cell differentiation antigen CD19 can act as rejection antigen. CD19(-/-) mice inoculated with CD19(+) B cell lymphoma cells showed higher survival rates than WT mice and were protected against additional tumor challenge. T cell depletion prior to tumor transfer completely abolished the protective response. By heterotypic vaccination of CD19(-/-) mice against murine CD19, survival after tumor challenge was significantly increased. To define protective epitopes within the CD19 molecule, T cells collected from mice that had survived the tumor transfer were analyzed for IFN? secretion in response to CD19-derived peptides. The majority of mice exhibited a CD4(+) T cell response to CD19 peptide 27, which was the most dominant epitope after CD19 vaccination. A peptide 27-specific CD4(+) T cell line protected CD19(-/-) mice against challenge with CD19(+) lymphoma and also cured a significant proportion of WT mice from recurrent disease in a model of minimal residual disease after chemotherapy. In conclusion, our data highlight CD19-specific CD4(+) T cells for adoptive T cell therapy of B cell lymphomas.
Authors with CRIS profile
Involved external institutions
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (HMGU) / Helmholtz Munich
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Max-Delbrück-Centrum für Molekulare Medizin / Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Germany (DE)
Technische Universität München (TUM)
Germany (DE)
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Max-Delbrück-Centrum für Molekulare Medizin / Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Germany (DE)
Technische Universität München (TUM)
Germany (DE)
How to cite
APA:
Lehmann, F.M., Maurberger, A., Feicht, S., Helm, F., Ladinig, C., Kieback, E.,... Bornkamm, G.W. (2014). Targeting high-grade B cell lymphoma with CD19-specific T cells. International Journal of Cancer, 135(5), 1153-64. https://doi.org/10.1002/ijc.28760
MLA:
Lehmann, Frank M., et al. "Targeting high-grade B cell lymphoma with CD19-specific T cells." International Journal of Cancer 135.5 (2014): 1153-64.
BibTeX: Download